KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TherapeuticsMD (TXMD) Retained Earnings (2016 - 2025)

TherapeuticsMD (TXMD) has disclosed Retained Earnings for 16 consecutive years, with -$951.8 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Retained Earnings changed 0.03% year-over-year to -$951.8 million, compared with a TTM value of -$951.8 million through Sep 2025, changed 0.03%, and an annual FY2024 reading of -$951.8 million, changed 0.23% over the prior year.
  • Retained Earnings was -$951.8 million for Q3 2025 at TherapeuticsMD, roughly flat from -$951.9 million in the prior quarter.
  • Across five years, Retained Earnings topped out at -$918.3 million in Q1 2021 and bottomed at -$1.1 billion in Q1 2022.
  • Average Retained Earnings over 5 years is -$971.5 million, with a median of -$951.9 million recorded in 2024.
  • The sharpest move saw Retained Earnings decreased 22.07% in 2021, then increased 14.31% in 2023.
  • Year by year, Retained Earnings stood at -$1.1 billion in 2021, then increased by 10.65% to -$939.4 million in 2022, then fell by 1.09% to -$949.6 million in 2023, then dropped by 0.23% to -$951.8 million in 2024, then grew by 0.01% to -$951.8 million in 2025.
  • Business Quant data shows Retained Earnings for TXMD at -$951.8 million in Q3 2025, -$951.9 million in Q2 2025, and -$952.5 million in Q1 2025.